stockrowAstraZeneca PLC
AZN Healthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +22.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
Follow AZN
Alert me
AstraZeneca PLC (AZN) Return on equity
AstraZeneca PLC's return on equity over the twelve months to 30 September 2026 was 22.6%, down 0.3 percentage points from fiscal 2025 (22.8%). Over the past ten years it has ranged from 0.41% (fiscal 2021) to 22.8% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers General industry median of 5.80% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 22.8% | 5.25 |
| FY2024 | 17.6% | 1.95 |
| FY2023 | 15.6% | 7.02 |
| FY2022 | 8.61% | 8.20 |
| FY2021 | 0.41% | (20.73) |
| FY2020 | 21.1% | 11.82 |
| FY2019 | 9.32% | (4.73) |
| FY2018 | 14.1% | (3.97) |
| FY2017 | 18.0% | (1.87) |
| FY2016 | 19.9% | 5.08 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| AMGN Amgen Inc. compare | 78.4% |
| NVO Novo Nordisk A/S compare | 60.8% |
| BMY Bristol Myers Squibb Company compare | 44.0% |
| NVS Novartis AG compare | 24.4% |
| AZN AstraZeneca PLC | 22.6% |
| PFE Pfizer Inc. compare | 4.42% |
| MRK Merck & Co., Inc. compare | 0.00% |
| GILD Gilead Sciences, Inc. compare | −22.5% |
| ABBV AbbVie Inc. compare | −288.7% |
| Drug Manufacturers General industry median | 5.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on AZN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement